Abingworth

Abingworth is a leading transatlantic life sciences investment firm. Abingworth became part of Carlyle (NASDAQ: CG) on 1 August 2022.

[Q32 Bio Inc. @Q32Bio]

Today Q32 Bio and Homology Medicines announced they have entered into a definitive merger agreement. The combined company will focus on advancing Q32’s wholly owned clinical candidates for #autoimmune and #inflammatorydiseases. Learn more: https://t.co/eJ1KvtH2Ew

[Abingworth @Abingworthbio]

Excited to announce the close of our new Clinical Co-Development Co-Investment Fund (CCD-CIF) at $356 million. The CCD-CIF continues to underpin our commitment to provide capital to partners advancing late-stage product development & bringing innovative medicines to patients

[Abingworth @Abingworthbio]

Kurt von Emster, Managing Partner and Head of Abingworth Life Sciences and Graham Mills, PhD, Investment Manager will participate in panels at Bio€quity Europe 2023 in Dublin, Ireland.
View the conference agenda: https://t.co/J7Na0isTCU

[Abingworth @Abingworthbio]

The University Spin-out Investment Terms (USIT) Guide has been published by @TenU_News in collaboration with UK universities and investors, including Abingworth. The guidance aims to accelerate and support the founding of start-ups from higher education. https://t.co/l7n4EQZYcL

[Abingworth @Abingworthbio]

Tim Haines, Executive Partner, will give a keynote speech 'Investment Trends for the Life Sciences Industry' at BioTrinity 2023 on Tuesday 25 April at 9:00 am BST in London, UK.
Find out more: https://t.co/mIUYvdZiqq

[Pixium-Vision @PixiumVision]

Pixium Vision announces #FDA Breakthrough Device Designation for the Prima System in Dry AMD

Read the Press Release: https://t.co/PGT2sOu0mv

#pixium #vision #AMD #DryAMD #medicaldevices #ophthalmology #PRIMA #clinicaltrials #reimbursement #healthcare #innovation #ALPIX #BVS

[Abingworth @Abingworthbio]

Portfolio company Launch Therapeutics has announced a strategic collaboration with @PathalysPharma to advance its therapeutic candidate upacicalcet through pivotal phase 3 studies for secondary hyperparathyroidism in dialysis patients.
Read the PR: https://t.co/uYcSG6Xlqn

[Jasper Therapeutics @JasperBio]

Today we announced positive clinical data from a Phase 1/2 trial of briquilimab as a conditioning treatment in #SickleCell disease and #BetaThalassemia. Read more about the ongoing study: https://t.co/51QMFTP9og

[Verona Pharma @VeronaPharma]

Verona Pharma ($VRNA) is pleased to announce positive #Phase3 data from its ENHANCE-1 trial in #COPD. The trial met the primary and key secondary endpoints demonstrating improvements in lung function, symptoms and quality of life. See more detail here:
https://t.co/oA7hg3hvZ0

[Abingworth @Abingworthbio]

Congratulations to portfolio company Soleno Therapeutics which has announced a financing commitment for up to $60 million from Abingworth, Nantahala Capital Management and Vivo Capital.

Read the press release from Soleno Therapeutics here:
https://t.co/dsoty37ia9

[Abingworth @Abingworthbio]

We are delighted to announce the appointment of Joy Ghosh as Managing Director. Welcome to the team Joy, great to have you on board!

https://t.co/oVjrtQV2Om

[Abingworth @Abingworthbio]

Congratulations to Avillion & @AstraZeneca as FDA Advisory Committee recommends PT027 as a new rescue treatment for asthma in adults. https://t.co/yzjhzXbLEA

[Abingworth @Abingworthbio]

Congratulations to our portfolio company Vaxcyte on its positive data from the Phase 1/2 proof-of-concept study evaluating VAX-24, a 24-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease.

https://t.co/UB1ko1Q2F8

[Abingworth @Abingworthbio]

Portfolio company Launch Therapeutics, formed with backing from Abingworth and @OneCarlyle to offer industry partners innovative models to provide funding and development expertise for late-stage clinical assets has announced its first partnership deal. https://t.co/8qxbe8Gz8z

[Phathom Pharmaceuticals @phathompharma]

#NEWS Today $PHAT announced the FDA has accepted our NDA for filing for the treatment of #ErosiveEsophagitis, with a PDUFA action date of January 11, 2023. Read more:

[Q32 Bio Inc. @Q32Bio]

We are proud to announce the initiation of the first-in-human phase 1 clinical study of ADX-097 for the treatment of complement disorders and look forward to continuing our work to develop biologic therapeutics for #autoimmune and #inflammatory diseases: https://t.co/eeSE75dO0e

[Abingworth @Abingworthbio]

Portfolio News: @exicure announced a $5 million private placement raise with participation from Abingworth. Proceeds are to support the advancement of preclinical candidates including its SCN9A product candidate, a non-opioid pain analgesic.

Read more: https://t.co/3QcHMBln3n

[Abingworth @Abingworthbio]

Portfolio News: Avillion LLP announced publication of the full positive results from the MANDALA Phase III trial of AstraZeneca 's PT027 in asthma patients in the New England Journal of Medicine.

Read more here: https://t.co/erEQvSzAja

[Phathom Pharmaceuticals @phathompharma]

#NEWS Today $PHAT announced the FDA has approved our two new therapies for treating H. pylori infection in adults. These regimens contain the first new class of acid-suppressant approved in the U.S. in over 30 years. Read more:
https://t.co/W6AYmqltQm

[Abingworth @Abingworthbio]

Portfolio News: HilleVax has announced the pricing of its upsized initial public offering of 11,765,000 shares of common stock at an initial public offering price of $17.00 per share on the NASDAQ Market.

Find out more: https://t.co/DZeN0tgo4x